Virax Biolabs (VRAX) Retained Earnings (2021 - 2023)

Virax Biolabs (VRAX) has 3 years of Retained Earnings data on record, last reported at -$11.8 million in Q1 2023.

  • For Q1 2023, Retained Earnings fell 86.12% year-over-year to -$11.8 million; the TTM value through Mar 2023 reached -$11.8 million, down 86.12%, while the annual FY2023 figure was -$11.8 million, 86.12% down from the prior year.
  • Retained Earnings reached -$11.8 million in Q1 2023 per VRAX's latest filing, down from -$6.3 million in the prior quarter.
  • Across five years, Retained Earnings topped out at -$4.6 million in Q1 2021 and bottomed at -$11.8 million in Q1 2023.
  • Average Retained Earnings over 3 years is -$7.6 million, with a median of -$6.3 million recorded in 2022.
  • Peak YoY movement for Retained Earnings: plummeted 36.92% in 2022, then plummeted 86.12% in 2023.
  • A 3-year view of Retained Earnings shows it stood at -$4.6 million in 2021, then tumbled by 36.92% to -$6.3 million in 2022, then tumbled by 86.12% to -$11.8 million in 2023.
  • Per Business Quant database, its latest 3 readings for Retained Earnings were -$11.8 million in Q1 2023, -$6.3 million in Q1 2022, and -$4.6 million in Q1 2021.